Maxime Brunet

@PTarantinoMD @myESMO Amazing poster! Curious — if T-DXd is stopped due to toxicity or patient choice without progression, has any data been presented comparing observation(no treatment) vs continued anti-HER2 therapy (like trastuzumab or pertuzumab)?

One of my favorite posters of #ESMOBreast25, addressing an important question: 👉What is the outcome of post-T-DXd treatments in HER2+ mBC? Does T-DXd-induced HER2 downregulation impair the activity of subsequent T-DM1? TKIs? Chemo? Answer below 1/4

What happened in breast cancer in 2024? A summary of important studies👇 #bcsm

#ESMO24 HR+/HER2- Breast Cancer The mutant-selective PI3Kα inhibitors STX-478 and RLY-2608 (combined with fulvestrant) have shown promising initial response rates in HR+/HER2- breast cancer patients. Both drugs demonstrated activity in kinase and helical domain mutations while showing significantly reduced hyperglycemia compared to alpelisib and inavolisib. This further confirms PI3Kα’s critical role as an essential isoform in insulin signaling and glucose metabolism, emphasizing the importance of preserving wild-type PI3Kα. However, the clinical data for RLY-2608 are based on its combination with fulvestrant, whereas STX-478 data are from monotherapy. The monotherapy data for STX-478 showed an objective response rate (ORR) of 21-23%, which is significantly higher than the 4-6% ORR typically seen with approved PI3K inhibitors. Even the clinical data for RLY-2608 presented at AACR23 primarily involved patients treated in combination with fulvestrant, making it difficult to assess RLY-2608’s standalone profile. In the near future, data on the mutant-selective PI3Kα H1047R inhibitor LOXO-783 are expected to be released. It will be exciting to examine this drug’s profile as well.

The largest #burnout survey in 2017 among European #YoungOncologists by ESMO confirmed that overall burnout prevalence was exceeding 70% with significant notable geographical differences (@BanerjeeSusana et al).

Je vous invite à regarder le numéro de complément d’enquête @Cdenquete diffusé ce soir sur les dérives des centres de santé présenté par @tristanwaleckx. C’est exactement ce contre quoi il faut nous battre et j’ai relevé quelques passages qui méritent un commentaire ⬇️

👩‍🦰 62yo with HR+/HER2- early breast cancer (cT1b cN0) underwent surgery. 🔬Diagnosis: IDC HG1, pT1c (bifocal 13+7), pN2 (4+/23, 1 with extracapsular extension). ER/PR (90%), HER2 1+, low ki67 (2-3%), sTILs <1%. 🧬Prosigna: Luminal A, ROR 14. ⁉️ Adjuvant treatment options?

Quand j’étais interne (je suis au 36 eme semestre), nous partions aux congrès internationaux invités par les laboratoires pharmaceutiques J’y ai beaucoup appris car il faut dire que les formations de 3 eme cycle sont très inégales J’ai pu y rencontrer des pairs seniors d’autres villes voire d’autres pays : très enrichissant ! Et tellement de sessions d’experts internationaux ! Et puis un jour un puriste mal luné a décidé qu’en tant qu’internes on était influençables … Pas une fois Chef de Clinique hein Interne … Et alors interdiction absolue de boire même un café dans une réunion locale ! Heureusement que les internes peuvent tout de même partir grâce à des associations Soutenues par l’industrie bien sûr Bah oui car ni les hôpitaux ni surtout l’Etat ne permet à des internes de participer à des congrès ! Tellement d’hypocrisie que je suis bien content d’avoir la liberté de partager cela avec vous J’ai boycotté tellement de réunions en soutien des internes Que ça en était presque risible pour certains Mais il faut avoir le courage de ses opinions Et entre nous : vu le prix des médicaments c’est bien normal que l’industrie pharmaceutique participe à la formation médicale 🎯

< 3 weeks to #ESMO23, here is a📝 of 🔑abstracts for general onc that could change our SoC! - #ALINA - #LIBRETTO431 - #TROPIONLung01 - #MARIPOSA - #Ev302 - #CM901 - #LITESPARK005 - #KN756 - #CABINET - #CODEBREAK300 #BCSM #GISM #LCSM #MedTwitter #GUSM #OncTwitter @myESMO

@PTarantinoMD Looking forward to seeing the results, especially EFS (OS?). Let's consider a HR+/ gBRCA+ CPS EG>2. Which adjuvant treatment: pembrolizumab, olaparib, abemaciclib, prolonged hormone therapy OSF...? Far from the era of de-escalation. We need biomarker strategy to select our pts.

Merck announces positive results for KEYNOTE-756: the addition of pembrolizumab to neoadjuvant chemo significantly improved pCR rate among patients with high-risk HR+/HER2- breast cancer. Follow up ongoing for EFS (co-primary endpoint). Poll below 👇 merck.com/news/merck-ann…

#AACR23 ✨Seminal work of @VanherseckeL @Brunet54 is highlighted in major symposium about TLS by @fridmanwh. Mature TLS is a major predictive biomarker of response to immune checkpoint inhibitors in solid tumors. @AACR @CRCordeliers @BERGONIE33 @NatureCancer @OncoAlert

Thanks to our mentors Antoine Italiano, @cousin_sophie, and Amandine Crombé for their guidance.

Exciting news from #AACR23 in Orlando! @BERGONIE33 is in full force with clinicians fellows from Bordeaux: Don't miss @MathildeLafon presenting groundbreaking work on radiomics in lung cancer. Up next: @FlorentPeyraud and I will be presenting our work on TLS.

Please help @TwitterSupport unlock @OncoAlert! The account was locked when the birthday was updated to relfect the start of the network-- in doing so the @TwitterBlue verified account was locked out due to Age restrictions. Thanks for the help-- and please retweet.

Aujourd'hui, la grève des confrères de médecine générale libérale se poursuit. Et, pour le moment, je n'en ai quasiment pas parler. Il serait temps qu'on s'explique ⤵⤵

@MathieuLrqt @Cancers_MDPI @LefortFelix @CHUBordeaux @OncoAlert 👏

Metastatic ccRCC : we discuss current treatment modalities, new approaches such as escalation/de-escalation strategies and innovative drugs in our last review article in @Cancers_MDPI mdpi.com/2072-6694/14/2… @LefortFelix @CHUBordeaux @OncoAlert

@MikaylaMDPhD @MathieuLrqt

MD/PhD trainees finishing 4 years of undergrad, 8 years of med/grad school, 3-7 years of residency, and 0-4 years of fellowship to finally start their career.

I’ve been working in clinical medicine for many years, and have picked up some habits for rapidly improving patient trust and faith in my care. Here are my top 5 "hacks" that I’ve picked up so far that you might want to try incorporating… (and pls let me know your own)

[#New] Recommandations @myESMO : la #télésurveillance en #oncologie a démontré une amélioration : - De la survie globale - De la qualité de vie - De l'observance des traitements & réduction des symptômes - Des arrêts de traitements et des hospitalisations en urgence

B cells, the new army to the forefront of immunotherapy. Enhancing immune response to cancer both by T cell activation and direct antibody-dependent cellular cytotoxicity! Beautiful review by @CRCordeliers crew. nature.com/articles/s4157…